Search

Your search keyword '"Leonardi S."' showing total 53 results

Search Constraints

Start Over You searched for: Author "Leonardi S." Remove constraint Author: "Leonardi S." Topic myocardial infarction Remove constraint Topic: myocardial infarction
53 results on '"Leonardi S."'

Search Results

1. Gender differences in the development of heart failure after acute coronary syndrome: Insight from the CORALYS registry.

2. Sex-specific presentation, care, and clinical events in individuals admitted with NSTEMI: the ACVC-EAPCI EORP NSTEMI registry of the European Society of Cardiology.

3. Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI.

4. Beneficial Effects of IABP in Anterior Myocardial Infarction Complicated by Cardiogenic Shock.

5. Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC).

6. Transient vs In-Hospital Persistent Acute Kidney Injury in Patients With Acute Coronary Syndrome.

7. A comprehensive and easy-to-use ECG algorithm to predict the coronary occlusion site in ST-segment elevation myocardial infarction.

8. Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study.

9. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.

10. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.

11. Return towards normality in admissions for myocardial infarction after the lockdown removal for COVID-19 outbreak in Italy.

12. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group.

13. Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY.

14. Cangrelor use in a 6-year-old patient undergoing complex percutaneous coronary intervention after post-surgical myocardial infarction.

15. Acute myocardial infarction complicating ischemic stroke: is there room for cangrelor?

16. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.

17. Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials.

18. Parenteral antithrombotic therapy during primary percutaneous coronary intervention.

19. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention.

20. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.

21. Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units Registry.

22. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).

23. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.

24. Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.

25. [Strategies for reducing door to balloon time in patients with acute myocardial infarction undergoing primary angioplasty: the Pavia experience].

26. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study.

28. Remote ischemic postconditioning as a strategy to reduce acute kidney injury during primary PCI: a post-hoc analysis of a randomized trial.

29. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.

30. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial.

31. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.

32. Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.

33. Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review.

34. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.

35. Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction.

37. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.

38. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

39. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

40. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

41. Effect of platelet inhibition with cangrelor during PCI on ischemic events

42. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.

43. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

44. Prediction of radial crossover in acute coronary syndromes

45. Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management

46. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial

47. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

48. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting

49. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). [Protocol]

50. Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome

Catalog

Books, media, physical & digital resources